Loading company…
Tremeau Pharmaceuticals is developing non-opioid pain therapies for chronic pain conditions.
Founded in 2016 and based in Cambridge, US, Tremeau Pharmaceuticals, Inc. develops non-opioid treatments for pain management. Gurnet Point Capital bought out the company in January 2019 for USD 59.3 mn, and Brad Sippy is its CEO. The directory describes its revenue as coming from partnerships with healthcare providers and possible pharmaceutical distribution agreements.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in